Spanish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
8 resultados
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
Dementia with Lewy Bodies (DLB) is an alpha-synucleinopathy and the second most common form of dementia in the elderly. DLB shares striking neuropathological and clinical similarities with both Parkinson's disease (PD) and Alzheimer's disease (AD). DLB and PD are characterized by death of
Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
This proposal will evaluate the effects of Bosutinib (Bosulif, Pfizer®) treatment - an FDA-approved tyrosine kinase inhibitor that targets c-Abelson (Abl) and Src tyrosine kinases- in patients with DLB. Investigators have demonstrated safety and efficacy of this compound in pre-clinical animal
Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
Idiopathic Parkinson's disease (PD) is a progressive neurodegenerative disorder of unknown etiology, characterized by bradykinesia (slowness of movements) associated with tremor at rest and/or muscle rigidity. PD is typically associated with a significant loss of dopaminergic neurons in the
Nilotinib in Huntington's Disease
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
The investigators performed an open label phase I clinical trial using two commercially available doses of Nilotinib (150 and 300mg capsules) in patients with advanced PDD and DLB. These indications have some overlapping pathologies and clinical symptoms and share common plasma and CSF biomarkers,
Clinical Laboratory Evaluation of Chronic Autonomic Failure
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
Objective:
In dysautonomias, altered functions of one or more components of the autonomic nervous system adversely affect health. A subset of dysautonomias consists of chronic autonomic failure (CAF) syndromes. A key sign of CAF is orthostatic hypotension (OH) due to sympathetic neurocirculatory
Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
In order for a subject to be considered for this study, the following criterion is required:
• Cognitive decline with mild cognitive impairment (Clinical Dementia Rating Stage 0.5) through moderate dementia (CDR Stages 1 and 2)
All patients, according to routine best practices will have an
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
Actual standard treatment for mild to moderately severe Alzheimer's dementia includes acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine) and a NMDA receptor antagonist (memantine for moderate to severe Alzheimer's disease). These medications have shown to have an effect on
Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
Overall study duration: 2 years. Planned inclusion period: 12 months. Study duration for individual patients: 4 months and 2 weeks(2 weeks between screening and randomization, 3 months of double-blind treatment and then a 4-week wash-out period).
Primary objective (V1 and V4):
To assess efficacy of
La base de datos de hierbas medicinales más completa respaldada por la ciencia
- Funciona en 55 idiomas
- Curas a base de hierbas respaldadas por la ciencia
- Reconocimiento de hierbas por imagen
- Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
- Leer publicaciones científicas relacionadas con su búsqueda
- Buscar hierbas medicinales por sus efectos.
- Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.
Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.
